In 2019, the genetic testing startup 23andMe made its debut on the Nasdaq stock exchange and soon achieved a valuation of more than $6 billion. This promising start did not last long, however, as the company’s share price steadily declined in the years that followed. The video below explores how 23andMe went from blockbuster brand to penny stock status as it encountered challenges with its business model as well as data privacy.
1. How did 23andMe’s business model limit Continue reading